Oklahoma is currently home to 945 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Oklahoma City, Tulsa, Norman and Edmond. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
NCT04720976
Recruiting
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2023
Locations: Research Site, Oklahoma City, Oklahoma
Conditions: Solid Tumor, NSCLC
Register for Updates
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
NCT04565015
Recruiting
The purpose of this study is to evaluate the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects with Primary Humoral Immunodeficiency (PHID).
Gender:
All
Ages:
Between 2 years and 16 years
Trial Updated:
05/15/2023
Locations: Oklahoma Institute of Allergy & Asthma Clinical Research, LLC, Oklahoma City, Oklahoma
Conditions: Primary Immune Deficiency
Register for Updates
Therapeutic Omegas for Triglyceride Suppression
NCT04349475
Recruiting
This study plans to learn more about how an omega-3 fatty acid supplement effects triglyceride levels in pregnancy. Triglycerides are a type of fat found in your blood. Your body converts extra calories into triglycerides to be stored and used later for energy. It is normal for triglyceride levels to go up during pregnancy however some women have levels that are ~30-40% higher than normal when they reach their third trimester of pregnancy. Having high triglycerides in pregnancy may be related to... Read More
Gender:
All
Ages:
Between 0 years and 39 years
Trial Updated:
05/09/2023
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Pregnancy
Register for Updates
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
NCT04509050
Recruiting
This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).
Gender:
All
Ages:
5 years and below
Trial Updated:
05/04/2023
Locations: Oklahoma Cystic Fibrosis Center, Oklahoma City, Oklahoma
Conditions: Cystic Fibrosis
Register for Updates
Dyadic Neurofeedback for Development of Healthy Emotion Regulation in Youth
NCT05472545
Recruiting
This study will examine the effect of a real-time functional magnetic resonance imaging (fMRI) dyadic neurofeedback protocol with mothers and their adolescent daughters. Mothers in the experimental condition will view a moving bar showing their daughters' brain activity on a computer screen while talking to their daughters.
Gender:
Female
Ages:
14 years and above
Trial Updated:
04/29/2023
Locations: Hardesty Center for Clinical Research and Neuroscience, Tulsa, Oklahoma
Conditions: Emotional Regulation
Register for Updates
A Study of DF6002 Alone and in Combination With Nivolumab
NCT04423029
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2023
Locations: Local Institution, Oklahoma City, Oklahoma
Conditions: Solid Tumors
Register for Updates
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. Until recently, the mainstay of treatment for these patients was supportive medical care. Howe... Read More
Gender:
All
Ages:
All
Trial Updated:
04/18/2023
Locations: Oklahoma University Medical Center, Oklahoma City, Oklahoma
Conditions: Spinal Muscular Atrophy (SMA)
Register for Updates
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
NCT04921345
Recruiting
The purpose of this study is to assess the pharmacokinetics (PK), efficacy, and safety of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 2 years and 12 years
Trial Updated:
04/05/2023
Locations: Galderma Investigational Site #8206, Norman, Oklahoma
Conditions: Moderate-to-Severe Atopic Dermatitis
Register for Updates
Antecedent Metabolic Health and Metformin Aging Study
NCT04264897
Recruiting
Aging is the number one risk factor for the majority of chronic diseases. There are no pharmaceutical treatments to slow aging and prolong healthspan. The anti-diabetic drug metformin is considered a likely pharmaceutical candidate to slow aging. In this study, the investigators hypothesize that metformin treatment in subjects free of type 2 diabetes will improve insulin sensitivity and glucoregulation in insulin resistant individuals, but will decrease insulin sensitivity and glucoregulation in... Read More
Gender:
All
Ages:
Between 40 years and 75 years
Trial Updated:
03/22/2023
Locations: University of Oklahoma Health Sciences Center, Oklahoma Shared Clinical and Translational Resources, Oklahoma City, Oklahoma
Conditions: Aging, Insulin Sensitivity, Chronic Disease, Mitochondria, Insulin Resistance
Register for Updates
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
NCT04726553
Recruiting
This study to examines the impact of anifrolumab on disease activity, immune phenotypes, and development of neutralizing antibodies to quadrivalent influenza vaccine in patients with Systemic Lupus Erythematosus (SLE). 10 patients with moderately to severely active SLE will be treated with anifrolumab in addition to standard of care lupus treatments and 10 will receive only standard of care medications. All will receive influenza vaccine.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/21/2023
Locations: Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma
Conditions: Systemic Lupus Erythematosus (SLE)
Register for Updates
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
All
Ages:
All
Trial Updated:
03/20/2023
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Breast Cancer
Register for Updates
Physica System Total Knee Replacement Registry Study
NCT03048201
Recruiting
The primary objective of this study is to obtain long-term implant survivorship (out to 10 years) and to assess clinical, patient-reported outcome measures, and radiographic data for the commercially available Physica system. For ancillary arm, from baseline to 5-year follow-up.
Gender:
All
Ages:
22 years and above
Trial Updated:
03/17/2023
Locations: Joint Reconstructive Specialist, Oklahoma City, Oklahoma
Conditions: Osteoarthritis, Knee, Traumatic Arthritis, Avascular Necrosis, Degenerative Joint Disease of Knee, Rheumatoid Arthritis, Deformity of Knee
Register for Updates